0K3W.L

Myriad Genetics, Inc. is a prominent company focused on genetic diagnostics and personalized medicine, operating across the United States and in international markets. The firm develops and commercializes a diverse range of molecular diagnostic tests, with applications primarily in oncology, women's health, and mental health. In its oncology segment, Myriad offers several key products: the MyRisk Hereditary Cancer Test, a DNA sequencing analysis to identify risks for inherited cancers; the BRACAnalysis CDx Germline Companion Diagnostic Test, which uses DNA sequencing to inform treatment decisions for patients with metastatic breast, ovarian, pancreatic, or prostate cancers who have deleterious or suspected deleterious germline BRCA variants; and the MyChoice CDx Companion Diagnostic Test, a tumor-based assessment to determine homologous recombination deficiency status in ovarian cancer patients. Other offerings include the Prolaris Prostate Cancer Prognostic Test, an RNA expression analysis to evaluate the aggressiveness of prostate cancer, and the EndoPredict Breast Cancer Prognostic Test, a similar RNA expression test for assessing breast cancer aggressiveness. The company also provides Precise Tumor, a solution aimed at precision oncology. For women's health, Myriad offers the Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to detect severe chromosomal disorders in a fetus. Additionally, the Foresight Carrier Screen is available, a prenatal test designed for prospective parents to understand their risk of passing on recessive genetic conditions to their offspring. Within the mental health sector, the GeneSight Psychotropic Mental Health Medication Test utilizes DNA genotyping to assist healthcare providers in selecting appropriate psychotropic medications for patients suffering from conditions such as depression, anxiety, and ADHD. Myriad Genetics, Inc. has established strategic collaborations with Illumina, Inc. and Intermountain Precision Genomics to offer comprehensive germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.